公开(公告)号：EP3527263A1

公开(公告)日：2019-08-21

申请号：EP18215671.1

申请日：2014-05-16

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHUO, Jincong ,  QIAN, Ding-Quan ,  MEI, Song ,  CAO, Ganfeng ,  PAN, Yongchun ,  LI, Qun ,  JIA, Zhongjiang

IPC分类号： A61P37/06 ,  C07D403/14 ,  A61K31/4155

摘要： The present invention provides compounds of Formula I:

or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：EP3231801B1

公开(公告)日：2019-02-13

申请号：EP17158350.3

申请日：2014-05-16

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHUO, Jincong ,  QIAN, Ding-Quan ,  MEI, Song ,  CAO, Ganfeng ,  PAN, Yongchun ,  LI, Qun ,  JIA, Zhongjiang

IPC分类号： C07D403/14 ,  A61K31/4155 ,  A61P37/00 ,  A61P35/00 ,  A61P29/00

公开(公告)号：EP2997023B1

公开(公告)日：2017-03-22

申请号：EP14732705.0

申请日：2014-05-16

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHUO, Jincong ,  QIAN, Ding-Quan ,  MEI, Song ,  CAO, Ganfeng ,  PAN, Yongchun ,  LI, Qun ,  JIA, Zhongjiang

IPC分类号： C07D403/14 ,  A61K31/4155 ,  A61P37/00 ,  A61P35/00 ,  A61P29/00

CPC分类号： C07D403/14

摘要： The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：EP3786162A1

公开(公告)日：2021-03-03

申请号：EP20201593.9

申请日：2014-05-16

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHUO, Jincong ,  QIAN, Ding-Quan ,  MEI, Song ,  CAO, Ganfeng ,  PAN, Yongchun ,  LI, Qun ,  JIA, Zhongjiang

IPC分类号： C07D403/14 ,  A61K31/4155 ,  A61P37/00 ,  A61P35/00 ,  A61P29/00

摘要： The present invention provides compounds of Formula I:

or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：EP3527263B1

公开(公告)日：2020-10-28

申请号：EP18215671.1

申请日：2014-05-16

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHUO, Jincong ,  QIAN, Ding-Quan ,  MEI, Song ,  CAO, Ganfeng ,  PAN, Yongchun ,  LI, Qun ,  JIA, Zhongjiang

IPC分类号： A61P37/06 ,  C07D403/14 ,  A61K31/4155

公开(公告)号：EP2997023A1

公开(公告)日：2016-03-23

申请号：EP14732705.0

申请日：2014-05-16

申请人： Incyte Corporation

发明人： LI, Yun-Long ,  ZHUO, Jincong ,  QIAN, Ding-Quan ,  MEI, Song ,  CAO, Ganfeng ,  PAN, Yongchun ,  LI, Qun ,  JIA, Zhongjiang

IPC分类号： C07D403/14 ,  A61K31/4155 ,  A61P37/00 ,  A61P35/00 ,  A61P29/00

CPC分类号： C07D403/14

摘要： The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

摘要翻译： 本发明提供了抑制Janus激酶（JAK）活性并可用于治疗与JAK活性有关的疾病的式I化合物或其药学上可接受的盐及其组合物和使用方法，包括 例如炎性疾病，自身免疫性疾病，癌症和其他疾病。

公开(公告)号：EP2049544B1

公开(公告)日：2010-11-03

申请号：EP07798941.6

申请日：2007-06-22

申请人： Incyte Corporation

发明人： METCALF, Brian ,  ZHANG, Ke ,  ZHENG, Changsheng ,  XUE, Chu-biao ,  CAO, Ganfeng ,  WANG, Anlai

IPC分类号： C07D487/14 ,  A61K31/522 ,  A61K31/519 ,  A61P3/10

CPC分类号： C07D487/14 ,  C07D403/14 ,  C07D487/04

摘要： The present invention relates to purinone derivatives of formula I which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

摘要翻译： 本发明涉及式I的嘌呤酮衍生物，它们是HM74a受体的激动剂。 进一步提供了使用本文化合物及其药学上可接受的盐用于治疗疾病的组合物和方法。

公开(公告)号：EP2049544A2

公开(公告)日：2009-04-22

申请号：EP07798941.6

申请日：2007-06-22

申请人： Incyte Corporation

发明人： METCALF, Brian ,  ZHANG, Ke ,  ZHENG, Changsheng ,  XUE, Chu-biao ,  CAO, Ganfeng ,  WANG, Anlai

IPC分类号： C07D487/14 ,  A61K31/522 ,  A61K31/519 ,  A61P3/10

CPC分类号： C07D487/14 ,  C07D403/14 ,  C07D487/04

摘要： The present invention relates to purinone derivatives of formula I which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.

公开(公告)号：EP2964650A1

公开(公告)日：2016-01-13

申请号：EP14712913.4

申请日：2014-03-05

申请人： Incyte Corporation

发明人： LIU, Pingli ,  WANG, Dengjin ,  WU, Yongzhong ,  CAO, Ganfeng ,  XIA, Michael

IPC分类号： C07D487/04 ,  C07F5/04 ,  C07D401/14

CPC分类号： C07D401/14 ,  C07D403/14 ,  C07D487/04 ,  C07F5/025 ,  C07F5/04

摘要： This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

公开(公告)号：EP2753621A1

公开(公告)日：2014-07-16

申请号：EP12770334.6

申请日：2012-09-06

申请人： Incyte Corporation

发明人： ZHOU, Jiacheng ,  LIU, Pingli ,  CAO, Ganfeng ,  WU, Yongzhong

IPC分类号： C07D487/04 ,  C07D491/10

CPC分类号： C07D491/113 ,  C07D401/06 ,  C07D487/04 ,  C07D491/10

摘要： This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

摘要翻译： 本发明涉及制备{1- {1- [3-氟-2-（三氟甲基）异烟酰基]哌啶-4-基} -3- [4-（7H-吡咯并[2,3-d] 嘧啶-4-基）-1H-吡唑-1-基]氮杂环丁烷-3-基}乙腈，可用于治疗与Janus激酶（JAK）的活性有关的疾病，包括炎症性疾病，自身免疫性疾病，癌症等 疾病。